Mirovan 2.5 Tablet

✔️ Dosage & Administration of Mirovan 2.5

• Adult dose: The initial dose for adults is 5 mg of Mirogabalin twice daily. Then the dose is gradually increased by 5 mg at an interval of at least a week to 15 mg twice daily. The dose may be adjusted appropriately between 10 mg and 15 mg twice daily depending on age and symptoms.
• Use in Children and Adolescents: It is not known if Mirogabalin is safe and effective in children and adolescents.
• Hepatic Impairment: A single 15 mg dose of Mirogabalin does not produce significant adverse reactions in patients with mild to moderate hepatic impairment. No data available for severe hepatic impairment.
• Renal Impairment: In mild renal dysfunction, the initial dose starts at 5 mg twice a day, slowly increased by 5 mg at an interval of 1 week to 10 mg. In moderate renal dysfunction, the initial dose starts at 2.5 mg twice a day, slowly increased by 2.5 mg at an interval of 1 week to 7.5 mg twice a day. In severe renal dysfunction, the initial dose starts at 2.5 mg once a day, slowly increased by 2.5 mg at an interval of 1 week to 7.5 mg once a day.

✔️ Mirogabalin is contraindicated in:

• patients hypersensitive to Mirogabalin.
• patients with mild to moderate Hepatic & Renal impairment.

✔️ Side Effects of Mirovan 2.5

• Lightheadedness, state close to sleep with impaired consciousness, loss of consciousness (dizziness, somnolence, unconsciousness).
• General malaise, loss of appetite, nausea, vomiting, jaundice (liver dysfunction).

✔️ Drug Interaction

With Medicine: Co-administration of Mirovan with Cimetidine or Probenecid may raise the Mirovan plasma concentration. Importantly, if Mirovan is taken with Lorazepam, the depressive effects on the CNS may be potentiated. Mirovan is OAT1, OAT3, OCT2, MATE1, MATE2-K and UGT substrate. Mirovan does not inhibit or induce major human CYP molecular species, and does not inhibit activities of drug transporters (including OAT1, OAT3, organic cation transporter OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, P-gp and BCRP). Co-administered with OAT1, OAT3, OCT2, MATE1, MATE2-K or UGT inhibitors may increase mirogabalin exposure, so use with caution.

With food & others: Administration of Mirovan with food has no clinically relevant effect on the total absorption of Mirovan. Avoid consuming alcohol while taking Mirovan, as Mirovan may potentiate the impairment of motor skills and sedating effects of alcohol.

✔️ Pregnancy & Lactation

For pregnant or potentially pregnant women, administer only if the therapeutic benefit outweighs the risks. Presence in placental tissue has been reported in animal studies. Consider the therapeutic and breastfeeding benefits, then consider continuing or discontinuing breastfeeding. It has been reported in animal studies that it is transferred into milk.

✔️ Safety Information:

This medicine may cause dizziness, somnolence, or loss of consciousness. Avoid operating dangerous machinery, such as driving a car. Especially for elderly patients, careful attention should be paid. This medicine may cause weight gain. This medicine may cause blurred vision and double vision.

If an allergic reaction occurs, stop taking the medicine and consult with a doctor. Dose adjustment is needed in patients with renal dysfunction. If taking any other medication, please consult with a doctor before administering Mirovan. As this medicine may cause dizziness or somnolence, the patient should avoid operating in potentially hazardous activities such as driving a car. Elderly patients should be aware of the risk of falls and fractures. The patient should consult with the doctor if signs of blurred vision or double vision appear while taking this medication.

✔️ Storage:

Store at below 30°C in a dry place, away from light and moisture. Keep out of the reach of children.